Abstract

The present study aims to evaluate the involvement of N-methyl-d-aspartate receptor and nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) system in antidepressant-like effects of Yueju pill (YJ), a Chinese herbal medicine. The immobility time in tail suspension test (TST) and forced swim test (FST) was used to assess the antidepressant effects. Prior administration of L-arginine (750 mg/kg, intraperitoneal [i.p.]), a NO synthase substrate that enhances NO signaling or sildenafil (5 mg/kg, i.p.), a phosphodiesterase 5 inhibitor that enhances cGMP, blunted the antidepressant-like activity of YJ (2.7 g/kg, i.g.). Co-treatment of ineffective dose of YJ (1.35 g/kg, i.g.) with one of the reagents that suppress the NO/cGMP signaling, including methylene blue (10 mg/kg, i.p.), an inhibitor of NO synthase; 7-NI (7-nitroinidazole, 30 mg/kg, i.p.), an nNOS specific inhibitor; L-NAME (10 mg/kg, i.p.), a non-specific inhibitor of NO synthase; and MK-801 (0.05 mg/kg, i.p.), an NMDA receptor antagonist, reduced the immobility time in TST and FST, compared with those in vehicle or single drug treatment groups. Neither above drugs alone or co-administrated with YJ affected locomotor activity or anxiety behavior in open field test. Thus, our results suggest that the antidepressant-like action of YJ may depend on the inhibition of NMDA/NO/cGMP pathway.

Highlights

  • Major depressive disorder (MDD) is a serious, disabling, and chronic recurring psychiatric illness that affects millions of individuals worldwide [1], and has a significant negative impact on public health [2]

  • Post hoc analyses indicated that NMDA alone could not affect the immobility time during behavior test

  • We examined the role of NMDA receptors and L-arginine/nitric oxide (NO)/cGMP pathway in the antidepressant-like activity of Yueju pill (YJ)

Read more

Summary

Introduction

Major depressive disorder (MDD) is a serious, disabling, and chronic recurring psychiatric illness that affects millions of individuals worldwide [1], and has a significant negative impact on public health [2]. Blockade of NMDA receptors displayed antidepressant activity, suggesting that glutamate played an important role in the depressive-like behaviors [6,7,8,9,10,11,12]. A typical non-competitive NMDA receptor, ketamine was demonstrated rapid antidepressant effect in both patients and rodents, especially in MDD or bipolar disorder [11,13]. The conventional antidepressants: SSRIs (selective serotonin reuptake inhibitors) had intense effect on NMDA receptor activity and could affect depressive behavior in MDD patients [14,15]. We found that the ethanol extract of Yueju pill (YJ), a traditional Chinese medicine, showed rapid antidepressant-like effect in acute and chronic animal models [16], and chronic YJ could improve the depressive behavior in patients [17]. Previous studies showed YJ as well as ketamine, License 4.0 (CC BY)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call